Compare Stocks: IMMX, PGEN, KLRA, and CDNA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CDNA CareDx	$46.38 +2.3%	$33.94	$11.27 ▼ $49.76	$2.34B	2.38	1.16 million shs	733,018 shs
IMMX Immix Biopharma	$11.34 +3.4%	$9.70	$1.94 ▼ $12.14	$784.79M	0.11	1.72 million shs	1.25 million shs
KLRA Kailera Therapeutics	$18.51 +3.2%	$19.41	$16.39 ▼ $28.23	$2.40B	N/A	420,313 shs	644,918 shs
PGEN Precigen	$6.55 +7.4%	$5.57	$2.62 ▼ $7.32	$2.17B	1.02	5.60 million shs	6.28 million shs

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CDNA CareDx	+2.34%	-1.47%	+16.74%	+125.91%	+291.72%
IMMX Immix Biopharma	+3.37%	+11.94%	+10.63%	+27.56%	+399.56%
KLRA Kailera Therapeutics	+3.18%	-2.48%	-0.22%	-5.66%	+1,850,999,900.00%
PGEN Precigen	+7.38%	-6.43%	+32.32%	+57.45%	+122.79%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CDNA CareDx	$46.38 +2.3%	$33.94	$11.27 ▼ $49.76	$2.34B	2.38	1.16 million shs	733,018 shs
IMMX Immix Biopharma	$11.34 +3.4%	$9.70	$1.94 ▼ $12.14	$784.79M	0.11	1.72 million shs	1.25 million shs
KLRA Kailera Therapeutics	$18.51 +3.2%	$19.41	$16.39 ▼ $28.23	$2.40B	N/A	420,313 shs	644,918 shs
PGEN Precigen	$6.55 +7.4%	$5.57	$2.62 ▼ $7.32	$2.17B	1.02	5.60 million shs	6.28 million shs

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CDNA CareDx	+2.34%	-1.47%	+16.74%	+125.91%	+291.72%
IMMX Immix Biopharma	+3.37%	+11.94%	+10.63%	+27.56%	+399.56%
KLRA Kailera Therapeutics	+3.18%	-2.48%	-0.22%	-5.66%	+1,850,999,900.00%
PGEN Precigen	+7.38%	-6.43%	+32.32%	+57.45%	+122.79%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CDNA CareDx	2.57	Moderate Buy	$47.75	2.95% Upside
IMMX Immix Biopharma	2.70	Moderate Buy	$21.29	87.70% Upside
KLRA Kailera Therapeutics	2.75	Moderate Buy	$42.75	130.96% Upside
PGEN Precigen	2.80	Moderate Buy	$14.50	121.37% Upside

Current Analyst Ratings Breakdown

Latest IMMX, PGEN, KLRA, and CDNA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2026	KLRA Kailera Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Sell (D)
8/14/2026	IMMX Immix Biopharma	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
8/13/2026	CDNA CareDx	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D+) ➝ Hold (C)
8/11/2026	IMMX Immix Biopharma	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$20.00 ➝ $19.00
8/10/2026	IMMX Immix Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$20.00 ➝ $25.00
8/6/2026	CDNA CareDx	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/6/2026	CDNA CareDx	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$45.00 ➝ $60.00
8/5/2026	PGEN Precigen	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$14.00 ➝ $18.00
8/5/2026	PGEN Precigen	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/3/2026	CDNA CareDx	Craig Hallum Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Buy	$64.00
8/3/2026	PGEN Precigen	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$14.00

(Data available from 8/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CDNA CareDx	$379.80M	6.32	N/A	N/A	$5.89 per share	7.87
IMMX Immix Biopharma	N/A	N/A	N/A	N/A	$1.77 per share	N/A
KLRA Kailera Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A
PGEN Precigen	$9.68M	241.23	N/A	N/A	$0.06 per share	109.17

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CDNA CareDx	-$21.35M	$2.07	22.41	73.62	N/A	24.23%	2.87%	2.17%	11/3/2026 (Estimated)
IMMX Immix Biopharma	-$29.44M	-$0.88	N/A	N/A	N/A	N/A	-38.44%	-34.72%	11/6/2026 (Estimated)
KLRA Kailera Therapeutics	-$148.96M	-$3,650.00	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PGEN Precigen	-$250.64M	-$1.04	N/A	7.62	N/A	-183.98%	423.75%	84.39%	N/A

Latest IMMX, PGEN, KLRA, and CDNA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	KLRA Kailera Therapeutics	-$0.74	-$1.09	-$0.35	-$1.09	N/A	N/A
8/7/2026	Q2 2026	IMMX Immix Biopharma	-$0.17	-$0.18	-$0.01	-$0.18	N/A	N/A
8/4/2026	Q2 2026	PGEN Precigen	-$0.0121	$0.05	+$0.0621	$0.05	$27.98 million	$54.98 million
7/30/2026	Q2 2026	CDNA CareDx	$0.2321	$0.37	+$0.1379	$2.07	$114.05 million	$131.95 million
5/26/2026	Q1 2026	KLRA Kailera Therapeutics	N/A	-$3,650.00	N/A	-$3,650.00	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CDNA CareDx	N/A	N/A	N/A	N/A	N/A
IMMX Immix Biopharma	N/A	N/A	N/A	N/A	N/A
KLRA Kailera Therapeutics	N/A	N/A	N/A	N/A	N/A
PGEN Precigen	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CDNA CareDx	N/A	4.58	4.51
IMMX Immix Biopharma	N/A	25.13	25.13
KLRA Kailera Therapeutics	N/A	11.11	11.11
PGEN Precigen	2.15	4.58	3.89

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CDNA CareDx	N/A
IMMX Immix Biopharma	11.26%
KLRA Kailera Therapeutics	N/A
PGEN Precigen	33.51%

Insider Ownership

Company	Insider Ownership
CDNA CareDx	2.40%
IMMX Immix Biopharma	30.30%
KLRA Kailera Therapeutics	N/A
PGEN Precigen	41.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CDNA CareDx	740	51.73 million	50.49 million	Optionable
IMMX Immix Biopharma	9	71.54 million	49.86 million	Optionable
KLRA Kailera Therapeutics	145	129.64 million	N/A	N/A
PGEN Precigen	190	356.51 million	208.92 million	Optionable

IMMX, PGEN, KLRA, and CDNA Headlines

Recent News About These Companies

Precigen (NASDAQ:PGEN) Stock Price Up 5.5% - Time to Buy?

August 17 at 12:40 PM | marketbeat.com

Analyzing Precigen (NASDAQ:PGEN) & Protara Therapeutics (NASDAQ:TARA)

August 17 at 2:28 AM | americanbankingnews.com

Precigen (NASDAQ:PGEN) Trading Down 5.5% - What's Next?

August 14, 2026 | marketbeat.com

Are You Looking for a Top Momentum Pick? Why Precigen, Inc. (PGEN) is a Great Choice

August 14, 2026 | zacks.com

Precigen (PGEN) Q2 2026 Earnings Call Transcript

August 12, 2026 | finance.yahoo.com

HC Wainwright Has Bullish Forecast for Precigen Q3 Earnings

August 9, 2026 | americanbankingnews.com

Insider Selling: Precigen (NASDAQ:PGEN) COO Sells 32,739 Shares

August 8, 2026 | insidertrades.com

Precigen: Has To Grow Into Its Valuation

August 8, 2026 | seekingalpha.com

Precigen (NASDAQ:PGEN) Raised to Strong-Buy at Wall Street Zen

August 8, 2026 | americanbankingnews.com

Wall Street Zen Upgrades Precigen (NASDAQ:PGEN) to "Strong-Buy"

August 8, 2026 | marketbeat.com

What is HC Wainwright's Estimate for Precigen Q4 Earnings?

August 8, 2026 | americanbankingnews.com

Precigen (NASDAQ:PGEN) COO Sells $224,589.54 in Stock

August 7, 2026 | marketbeat.com

Precigen (NASDAQ:PGEN) Stock Rating Upgraded by Zacks Research

August 7, 2026 | marketbeat.com

HC Wainwright Has Positive Outlook for Precigen Q3 Earnings

August 7, 2026 | marketbeat.com

Precigen (NASDAQ:PGEN) Shares Gap Up After Strong Earnings

August 7, 2026 | americanbankingnews.com

Precigen: 'Strong Buy' Papzimeos Cash-Flow Breakeven In '26, PRGN-2009 Advancement

August 6, 2026 | seekingalpha.com

HC Wainwright Predicts Precigen's Q4 Earnings (NASDAQ:PGEN)

August 6, 2026 | marketbeat.com

Precigen (NASDAQ:PGEN) Reaches New 12-Month High - Should You Buy?

August 6, 2026 | marketbeat.com

Arrowstreet Capital Limited Partnership Acquires Shares of 395,695 Precigen, Inc. $PGEN

August 6, 2026 | marketbeat.com

Precigen Inc (PGEN) (Q2 2026) Earnings Call Highlights: Revenue Surges 145% and Net Profit Achieved

August 5, 2026 | finance.yahoo.com

Precigen (NASDAQ:PGEN) Shares Gap Up on Better-Than-Expected Earnings

August 5, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMMX, PGEN, KLRA, and CDNA Company Descriptions

CareDx NASDAQ:CDNA

$46.38 +1.06 (+2.34%)

Closing price 08/17/2026 04:00 PM Eastern

Extended Trading

$46.64 +0.26 (+0.56%)

As of 07:03 AM Eastern

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.

Immix Biopharma NASDAQ:IMMX

$11.34 +0.37 (+3.37%)

Closing price 08/17/2026 04:00 PM Eastern

Extended Trading

$11.42 +0.07 (+0.66%)

As of 06:31 AM Eastern

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.

Kailera Therapeutics NASDAQ:KLRA

$18.51 +0.57 (+3.18%)

As of 08/17/2026 04:00 PM Eastern

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives. With our obesity-first focus, we have built a diversified pipeline of product candidates specifically designed to address critical needs in the current therapeutic landscape with a lead product candidate that we believe offers the potential for the greatest weight loss. We are rapidly progressing four clinical-stage product candidates, leveraging multiple glucagon-like peptide-1, or GLP-1, based mechanisms of action and routes of administration. Our lead product candidate, ribupatide (also known as KAI-9531), is currently being evaluated in global Phase 3 trials as a once-weekly injectable GLP-1/glucose-dependent insulinotropic polypeptide, or GIP, receptor dual agonist peptide that we believe offers the potential for the greatest weight loss compared to all obesity management medications currently marketed or in development with a tolerability profile that is class-like or better. We are expanding our ribupatide franchise by developing a once-daily oral tablet formulation, oral ribupatide, based on the same peptide as injectable ribupatide, to provide a convenient oral option with the potential for highly differentiated tolerability with compelling weight loss among oral treatments. Additionally, we are advancing a second oral product candidate, KAI-7535, a once-daily small molecule GLP-1 receptor agonist with the potential to improve on the clinical profile of existing oral treatments. Finally, we are developing KAI-4729, a once-weekly injectable GLP-1/GIP/glucagon receptor tri-agonist, that leverages an incremental mechanism to potentially deliver compelling weight loss, improved liver fat reduction and a differentiated tolerability profile. KAI-4729 is based on a different peptide than injectable ribupatide and oral ribupatide. Obesity is a chronic, complex disease characterized by the accumulation of excessive body fat, resulting in significant negative impacts on health and quality of life. The most severely impacted patient population, people with a body mass index, or BMI, of 35 kg/m2 or greater, which we refer to as a BMI of 35+, represents the fastest growing and largest segment of this population, with half of U.S. adults with obesity expected to have a BMI of 35+ by 2030. While the approvals of GLP-1-based obesity management medications have changed the landscape of obesity management, there remains a critical need for medications offering greater weight loss, especially for those living with a higher BMI. For example, in the SURMOUNT-1 Phase 3 clinical trial, the majority of patients who had a baseline BMI of 35+ and were treated with tirzepatide, the most prescribed weight loss medicine today, were still living with obesity at the end of treatment. Both physicians and patients have identified expected weight loss as a primary treatment goal, with the magnitude of weight reduction serving as a crucial driver in therapy selection. We believe that injectable treatments will remain foundational for patients needing significant weight reduction. Meanwhile, for patients with a lower BMI, lower incidences of gastrointestinal side effects may be needed to achieve optimal weight loss and treatment persistence, and we believe oral treatments can unlock adoption for those with more modest weight loss needs, while also supporting the chronic treatment journey of those living with higher BMIs. We were originally incorporated under the laws of the State of Delaware on May 8, 2024 under the name Hercules CM Newco, Inc. We changed our name to Kailera Therapeutics, Inc. on August 22, 2024. Our principal executive offices are located in Waltham, Massachusetts.

Precigen NASDAQ:PGEN

$6.55 +0.45 (+7.38%)

Closing price 08/17/2026 04:00 PM Eastern

Extended Trading

$6.63 +0.08 (+1.16%)

As of 07:01 AM Eastern

Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IMMX, PGEN, KLRA, and CDNA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IMMX, PGEN, KLRA, and CDNA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IMMX, PGEN, KLRA, and CDNA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMMX, PGEN, KLRA, and CDNA Company Descriptions

CareDx NASDAQ:CDNA

Immix Biopharma NASDAQ:IMMX

Kailera Therapeutics NASDAQ:KLRA

Precigen NASDAQ:PGEN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IMMX, PGEN, KLRA, and CDNA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IMMX, PGEN, KLRA, and CDNA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IMMX, PGEN, KLRA, and CDNA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMMX, PGEN, KLRA, and CDNA Company Descriptions

CareDx NASDAQ:CDNA

Immix Biopharma NASDAQ:IMMX

Kailera Therapeutics NASDAQ:KLRA

Precigen NASDAQ:PGEN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools